In-situ injectable thermosensitive gel based on poloxamer as a new carrier for Tamoxifen citrate

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 5, Issue SUPPL.4, 2013, Pages 429-437

  Shaker, Dalia S ^a   Ghorab, Mohamed K ^a   Klingner, Anke ^b   Teiama, Mohamed S ^a  

^a HELWAN UNIVERSITY   (Egypt)

^b German University in Cairo   (Egypt)

Author keywords

Inclusion complex; Injectable hydrogel; SBE Cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; POLOXAMER; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG RELEASE; DRUG RETENTION; EXCIPIENT COMPATIBILITY; FEMALE; GEL; GELATION; INFRARED SPECTROSCOPY; NONHUMAN; RAT; TEMPERATURE; THERMOSENSITIVE GEL;

EID: 84888369330     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Powles TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 1992; 340 (8828): 1145-1147.
2. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13 (2): 513-529.
3. Stone R. NIH fends off critics of tamoxifen study. Science 1992; 258 (5083): 734.
4. Jagabeesh HG, Deviv K. Tamoxifen loaded poly (e{open}caprolactone) based injectable microspheres for breast cancer. Int J Pharm Pharm Sci. 2010; 2 (4): 189-195.
5. Gao S, Singh J. In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes. J Control Release 1998; 51 (2-3): 193-199.
6. Srikanth MV, Murali Mohan Babu GV, Sreenivasa Rao N, Sunil SA, Balaji S, et al. Dissolution rate enhancement of poorly soluble Bicalutamide using β-Cyclodextrin inclusion complexation. Int J Pharm Pharm Sci 2010; 2(1): 191-198.
7. Ghorab MK, Adeyeye MC. Enhancement of ibuprofen dissolution via wet granulation with beta-cyclodextrin. Pharm Dev Technol 2001; 6 (3): 305-314.
8. Ghorab MK, Adeyeye MC. Enhanced bioavailability of processinduced fast-dissolving ibuprofen cogranulated with betacyclodextrin. J Pharm Sci 2003; 92 (8): 1690-1697.
9. Szejtli J. Introduction and General Overview of Cyclodextrin Chemistry. Chem Rev 1998; 98 (5): 1743-1754.
10. Talasaz AHH, Ghahremankhani AA, Moghadam SH, Malekshahi MR, Atyabi, F, Dinarvand R. In situ gel forming systems of poloxamer 407 and hydroxypropyl cellulose or hydroxypropyl methyl cellulose mixtures for controlled delivery of vancomycin. J Appl Polm 2008; 109: 2369-2374.
11. Bromberg L. Self-Assembly in Aqueous Solutions of Polyether-Modified Poly(acrylic acid). Langmuir 1998; 14 (20): 5806-5812.
12. Conte U, Colombo P, Gazzaniga A, Sangalli ME, La Manna A. Swelling-activated drug delivery systems. Biomaterials 1988; 9 (6): 489-493.
13. Couffin-Hoarau AC, Motulsky A, Delmas P, Leroux JC. In situforming pharmaceutical organogels based on the self-assembly of L-alanine derivatives. Pharm Res 2004; 21 (3): 454-457.
14. Beyssac E, Bregni C, Aiache JM, Smolko E. Hydrogel implants for methotrexate obtained by ionizing radiation. Drug Del Ind Pharm 1996; 22 (2): 439-444.
15. He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release 2008; 127 (3): 189-207.
16. Ruel-Gariepy E, Leroux, JC. In situ-forming hydrogels--review of temperature-sensitive systems. Eur J Pharm Biopharm 2004; 58 (2): 409-426.
17. Dumortier G, Grossiord JL, Zuber M, Couarraze G, Chaumeil JC. Thermoreversible morphine gel. Drug Del Ind Pharm 1991; 17 (9): 1255-1265.
18. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002; 19 (1): 1-72.
19. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23 (12): 2709-2728.
20. Juhasz J, Lenaerts V, Raymond P, Ong H. Diffusion of rat atrial natriuretic factor in thermoreversible poloxamer gels. Biomaterials 1989; 10 (4): 265-268.
21. Albers E, Muller BW. Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst 1995; 12 (4): 311-337.
22. Thompson DO. Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst 1997; 14 (1): 1-104.
23. Choi HG, Jung JH, Ryu JM, Yoon SJ, Oh YK, Kim CK. Development of in situ gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm 1998; 165: 33-44.
24. Miyazaki S, Nakamura T, Takada M. Thermo-sensitive sol-gel transition of Pluronic F-127. Yakuzaigaku 1991; 51: 36-43.
25. Crassous JJ, Regisser R, Ballauff M, Willenbacher N. Characterization of the viscoelastic behavior of complex fluids using the piezoelastic axial vibrator. J Rheol 2005; 49 (4): 851-863.
26. Smith BA, Tolloczko B, Martin JG, Peter Grutter P. Probing the viscoelastic Behavior of Cultured Airway Smooth Muscle Cells with Atomic Force Microscopy: Stiffening Induced by Contractile Agonist. Biophys J 2005; 8(4): 2994-3007.
27. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 1975; 27 (1): 48-49.
28. Anderson NH, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. J Pharm Biomed Anal 1998; 17 (4-5): 811-822.
29. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res 1991; 51: 4837-4844.
30. Pathan IB, Setty CM. Enhancement of Transdermal Delivery of Tamoxifen Citrate using Nanoemulsion Vehicle. Int J Pharm Tech Res 2011; 3 (1): 287-297.
31. El-Arini SK, Giron D, Leuenberger H. Solubility properties of racemic praziquantel and its enantiomers. Pharm Dev Technol 1998; 3 (4): 557-564.
32. Donald AG, Cody JW, Linda AF. Using cyclodextrin complexation to enhance secondary photoprotection of topically applied ibuprofen. Europ J Pharm Biopharm 2006; 62: 85-93.
33. Bettinetti GP, Sorrenti M, Rossi S, Ferrari F, Mura P, Faucci MT. Assessment of solid-state interactions of naproxen with amorphous cyclodextrin derivatives by DSC. J Pharm Biomed Anal 2002; 30 (4): 1173-1179.
34. Bordwell F G and Donald, A. Nitrogen acids. 1. Carboxamides and sulfonamides. J Org Chem 1976; 41 (14): 2507-2508.
35. Lockwood SF, O'Malley S, Mosher GL. Improved aqueous solubility of crystalline astaxanthin (3, 3'-dihydroxy-beta, betacarotene-4, 4'-dione) by Captisol (sulfobutyl ether betacyclodextrin). J Pharm Sci 2003; 92 (4): 922-926.
36. Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007; 329 (1-2): 1-11.
37. Frank DW, Gray JE, Weaver RN. Cyclodextrin nephrosis in the rat. Am J Pathol 1976; 83 (2): 367-382.
38. Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ, Thompson DO. Preliminary safety evaluation of parenterally administered sulfoalkyl ether beta-cyclodextrin derivatives. J Pharm Sci 1995; 84 (8): 927-932.
39. Totterman AM, Schipper NG, Thompson DO, Mannermaa JP. Intestinal safety of water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: effects on human intestinal epithelial Caco-2 cells. J Pharm Pharmacol 1997; 49 (1): 43-48.
40. Nagase Y, Arima H, Wada K, Sugawara T, Satoh H, Hirayama F, Uekama K. Inhibitory effect of sulfobutyl ether betacyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies. J Pharm Sci 2003; 92 (12): 2466-2474.
41. Schmolka IR. I'm A review of block polymer surfactant. J Am Oil Chem Soc 1977; 54: 110-116.
42. Chang JY, Oh YK, Choi HG, Kim YB, Kim, CK. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm 2002; 241 (1): 155-163.
43. Almdal K, Dyre, J, Hvidt S, Kramer, O. Towards a phenomenological definition of the term gel. Polym Gel Netw 1993; 1 (1): 5-17.
44. Miller SC and Drabik BR. Rheological properties of poloxamer vehicle. Int J Pharm 1984; 18 (3): 269-276.
45. Vincent Lenaerts, Caroline Triqueneaux, Michel Quartern, Francoise Rieg-Falson Couvreur, P. Temperature-dependent rheological behavior of Pluronic F-127 aqueous solutions. Int J Pharm 1987; 39 (1-2): 121-127.
46. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 1989; 37 (4): 451-490.
47. Buchanan CM, Buchanan NL, Edgar KJ, Little JL, Malcolm MO, Ruble KM, Wacher VJ, Wempe MF. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifenhydroxybutenyl-beta-cyclodextrin formulations. J Pharm Sci 2007; 96 (3): 644-660.
48. Le UM, Shaker DS, Sloat BR, Cui Z. A thermo-sensitive polymeric gel containing a gadolinium (Gd) compound encapsulated into liposomes significantly extended the retention of the Gd in tumors. Drug Dev Ind Pharm 2008; 34 (4): 413-418.
49. Fattal E, De Rosa G, Bochot A. Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acids. Int J Pharm 2004; 277 (1-2): 25-30.